Non-profit gets PRV, FDA approval for river blindness drug

Medicines Development for Global Health (Southbank, Australia) said FDA approved its NDA for moxidectin to treat onchocerciasis, commonly known as river blindness, in patients at least 12 years old. MDGH received a Priority Review voucher along with the approval, marking the first time a non-profit has registered a product and received a voucher through the tropical disease PRV program...